Shanghai Fosun Pharmaceutical (600196.SH) subsidiary's HLX109 injection approved to conduct clinical trials in Australia
Shanghai Fosun Pharmaceutical (600196.SH) announced that recently, the Phase I clinical trial protocol for HLX109 injection (a monoclonal antibody targeting IL1RAP) independently developed by the company's controlled subsidiary Shanghai Henlius Biotech, Inc. and its controlled subsidiaries (collectively "Henlius"), for the treatment of generalized pustular psoriasis, has been approved by the relevant Human Research Ethics Committee and filed with the Australian Therapeutic Goods Administration. This is the first clinical trial approval obtained for this drug worldwide. Henlius plans to conduct the relevant clinical research of this drug in Australia once conditions are met.
Shanghai Fosun Pharmaceutical (600196.SH) announced that recently, the Phase I clinical trial protocol for HLX109 injection (i.e., an IL1RAP-targeting monoclonal antibody) independently developed by the company's controlled subsidiary Shanghai Henlius Biotech, Inc. and its controlled subsidiaries (collectively "Henlius") for the treatment of generalized pustular psoriasis was approved by the relevant Human Research Ethics Committee and filed with the Australian Therapeutic Goods Administration, marking the first clinical trial approval obtained for this drug globally. Henlius plans to conduct the relevant clinical research for this drug in Australia once conditions are met.
Related Articles
YEAHKA (09923) repurchased 28,800 shares for HK$99,000 on November 4.
LAI FUNG HOLD (01125): Public shareholding stands at 14.76%
WEIGAO GROUP (01066) repurchased 220,000 shares on November 4 for HK$692,600.
YEAHKA (09923) repurchased 28,800 shares for HK$99,000 on November 4.
LAI FUNG HOLD (01125): Public shareholding stands at 14.76%
WEIGAO GROUP (01066) repurchased 220,000 shares on November 4 for HK$692,600.
